Services for Colloidal Gold Lateral Flow Assays to Accelerate Point-of-Care Diagnostics

steven rios — Tue, 26 May 2026 05:09:12 +0000

LFA is a paper-based platform used to detect and quantify analytes in complex mixtures. The procedure involves placing a sample on the test device and obtaining results within 5 to 30 minutes. Depending on the recognition element used, LFAs can be broadly classified into two categories. Lateral flow immunoassays are utilized as recognition elements. Nucleic acid lateral flow assays detect amplicons that may be formed during the polymerase chain reaction (PCR) process. LFAs are inexpensive to produce and simple to operate. Importantly, they have also been widely accepted by users and regulatory authorities, making them well-suited to meeting the growing demand for point-of-care, multiplexed diagnostic testing.

Colloidal gold LFAs offer numerous advantages, such as a visible colour reaction that facilitates rapid detection and specific labelling. Furthermore, they are highly stable and suitable for large-scale production, and are also well-suited to home or on-site testing. They possess multiplexing capabilities, high sensitivity, and quantitative potential when used with dedicated equipment, eliminating the need for expensive specialized equipment.

CD Bioparticles offers custom services to assist researchers in developing colloidal gold lateral flow immunoassay products. The company's services range from customizing nanoparticle conjugates to optimizing complete LFA systems. CD Bioparticles can provide comprehensive support to clients throughout the entire process, including feasibility studies, initial development stages and the final commercialisation phase.

A dedicated technical support team is available to answer clients' queries and discuss project requirements in detail. This team provides timely progress reports at each stage and offers post-delivery assistance as required. The team has extensive experience in delivering comprehensive services covering sample preparation, critical material selection, experimental protocol design, and validation. The company is also highly skilled in optimizing running buffers, conjugation methods and nanoparticles. CD Bioparticles can help clients transfer and optimize existing proof-of-concept assays into rapid, flow cytometry-based diagnostic solutions.

Furthermore, the company has the capability to produce high-quality, low-cost nanoparticles for rapid diagnostic testing, including gold colloids, upconversion nanoparticles and quantum dots. The company can supply uniform nanoparticles with varying sizes and surface properties for LFA development. Large-scale production combined with years of stability testing enables clients to minimize production risks.

CD Bioparticles conducts comprehensive characterization analyses on all particles to ensure that every batch meets specification requirements. Strict quality control measures are implemented at every stage of the LFA development process to ensure the final product is highly accurate, reliable and consistent.

For more information about CD Bioparticles' Colloidal Gold Lateral Flow Assay development services, please visit https://www.cd-bioparticles.com/services/colloidal-gold-lateral-flow-assay-development.html.

Organoid Culture Tools to Advance 3D Disease Modeling and Drug Discovery

steven rios — Tue, 26 May 2026 02:35:55 +0000

Organoids are simple cell-based in vitro tissue engineering models that can reproduce many aspects of the complex structure and function of their corresponding in vivo tissues. They can be dissected and analyzed to study the fundamental mechanisms of human tissue development, regeneration, and repair. They can also be used for diagnostics, disease modelling, drug development, and personalized medicine. Organoids can be derived from pluripotent stem cells, tissue-resident stem cells (embryonic or adult), progenitor cells or differentiated cells from healthy or diseased tissues (such as tumors). A large number of organoid engineering strategies supporting the culture, growth, proliferation, differentiation and maturation of organoids have been reported to date.

Complex, three-dimensional organoids represent a unique research tool, offering significant advantages over overly simplified, two-dimensional cell culture systems and animal models, which often fail to accurately replicate human physiological and pathological conditions. As the scientific community moves away from traditional two-dimensional cell culture and seeks alternatives that more closely mimic the human body than animal experiments do, CD Bioparticles' organoid culture tools provide the key building blocks for constructing these 'mini-organs', thus facilitating breakthroughs in cancer research, regenerative medicine, and personalized drug screening.

The newly released product line includes Human-Derived Normal Organoid Kits, Human-Derived Tumor Organoid Kits, Mouse-Derived Normal Organoid Kits, and Organoid-Related Reagents. For example, CD Bioparticles' Tumor Organoid Kits (Human-Derived) are designed to help researchers construct three-dimensional models that closely replicate the native tumour microenvironment. The range includes kits for various common tumour types and is intended to advance cancer research by facilitating more precise and efficient experimental methods and accelerating the development of personalized cancer therapies.

CD Bioparticles' kits provide a comprehensive solution, combining tumour tissue processing, organoid culture, passaging, cryopreservation, and thawing. They support the efficient establishment of tumour organoid models using primary samples obtained from surgical resection or biopsy with excellent reproducibility and a high success rate. Thanks to optimized formulations and standardized operating procedures, the resulting organoids retain the original tumour's key characteristics, including tissue structure, genetic mutation profiles, cellular heterogeneity, and drug response profiles. These properties make the organoids an ideal choice for applications, such as personalized medicine research, anti-cancer drug screening, high-throughput drug sensitivity testing, and cancer mechanism studies.

For more information on the Organoid Culture Tools or to view the full product catalog, please visit CD Bioparticles at https://www.cd-bioparticles.net/products/organoid-culture-tools.html.

Spring Builders: steven rios

Services for Colloidal Gold Lateral Flow Assays to Accelerate Point-of-Care Diagnostics

Organoid Culture Tools to Advance 3D Disease Modeling and Drug Discovery